Cheaper AMD drug could lead to serious eye issues

A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.

"This is a very important finding," says Sanjay Sharma ( and Epidemiology), a noted AMD and researcher who also practices at Hotel Dieu Hospital. "It is particularly important because many seniors need numerous injections so the risk is cumulative."

AMD is the leading cause of severe visual loss and in Canada. It is linked to depression, falls and higher rates of nursing home admissions.

The research reviewed cases of patients who received consecutive injections of either the more expensive or the cheaper version of the drug. Patients receiving the cheaper drug had a 12 times higher risk of serious eye inflammation and some patients also lost their sight, according to the study.

Many provincial governments are considering the use of the cheaper drug to help curb spiraling costs. The more expensive drug retails for $1,800 while the cheaper version is one-tenth of that price.

Related Stories

Novartis tries to make UK hospitals use $1000 drug

date Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

Report shows risk of blindness halved over last decade

date Jan 19, 2012

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases ...

Recommended for you

Lowering risk of a major eye disease

date May 20, 2015

Age-related macular degeneration (AMD), a chronic, progressive disease, is a leading cause of blindness among people aged 65 and older. Vision impairment due to advanced AMD significantly reduces quality ...

Age-related macular degeneration, mortality linked

date May 12, 2015

(HealthDay)—Age-related macular degeneration (AMD) is a predictor of poor survival, especially among women aged 80 years and older, according to a study published online May 4 in the Journal of the American Ge ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.